List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2968752/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Persistent HIVâ€controllers are more prone to spontaneously clear HCV: a retrospective cohort study. Journal of the International AIDS Society, 2020, 23, e25607.	3.0	2
2	Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients. Frontiers in Genetics, 2020, 11, 497.	2.3	13
3	Indicator condition-guided HIV testing with an electronic prompt in primary healthcare: a before and after evaluation of an intervention. Sexually Transmitted Infections, 2019, 95, 238-243.	1.9	11
4	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet, The, 2019, 393, 2428-2438.	13.7	627
5	Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. Journal of Microbiology, Immunology and Infection, 2019, 52, 667-671.	3.1	14
6	Proteomic Profile Associated With Loss of Spontaneous Human Immunodeficiency Virus Type 1 Elite Control. Journal of Infectious Diseases, 2019, 219, 867-876.	4.0	23
7	Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers. BMC Medicine, 2018, 16, 30.	5.5	19
8	Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men. Clinical Microbiology and Infection, 2018, 24, 540-545.	6.0	13
9	Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. Journal of Virology, 2018, 92, .	3.4	58
10	Role of APOBEC3H in the Viral Control of HIV Elite Controller Patients. International Journal of Medical Sciences, 2018, 15, 95-100.	2.5	2
11	High Plasma Levels of sTNF-R1 and CCL11 Are Related to CD4+ T-Cells Fall in Human Immunodeficiency Virus Elite Controllers With a Sustained Virologic Control. Frontiers in Immunology, 2018, 9, 1399.	4.8	3
12	Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. Journal of Antimicrobial Chemotherapy, 2017, 72, 2857-2861.	3.0	12
13	Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression. Frontiers in Immunology, 2017, 8, 836.	4.8	10
14	Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination. Aids, 2016, 30, 553-562.	2.2	6
15	Rate and predictors of progression in elite and viremic HIV-1 controllers. Aids, 2016, 30, 1209-1220.	2.2	69
16	An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis. Trials, 2016, 17, 163.	1.6	36
17	Predictive Factors for HIV Seroconversion Among Individuals Attending a Specialized Center After an HIV Risk Exposure: A Case–Control Study. AIDS Research and Human Retroviruses, 2016, 32, 1016-1021.	1.1	4
18	A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. Journal of Antimicrobial Chemotherapy, 2016, 71, 1982-1986.	3.0	9

#	Article	IF	CITATIONS
19	A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. Journal of Antimicrobial Chemotherapy, 2016, 71, 1987-1993.	3.0	16
20	Analysis of Non-AIDS-Defining Events in HIV Controllers. Clinical Infectious Diseases, 2016, 62, 1304-1309.	5.8	34
21	Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1. Journal of Leukocyte Biology, 2016, 99, 349-359.	3.3	20
22	Shared Care Unit: a new model of coordinating HIV care between Primary Settings and Hospital. International Journal of Integrated Care, 2016, 16, 200.	0.2	1
23	Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture. Aids, 2015, 29, 1309-1318.	2.2	10
24	HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. Journal of Virology, 2015, 89, 9189-9199.	3.4	33
25	Association of microbial translocation biomarkers with clinical outcome in controllers HIV-infected patients. Aids, 2015, 29, 675-681.	2.2	31
26	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. Journal of Antimicrobial Chemotherapy, 2015, 70, 1833-1842.	3.0	56
27	Alternative Effector-Function Profiling Identifies Broad HIV-Specific T-Cell Responses in Highly HIV-Exposed Individuals Who Remain Uninfected. Journal of Infectious Diseases, 2015, 211, 936-946.	4.0	18
28	Differential MicroRNA Expression Profile between Stimulated PBMCs from HIV-1 Infected Elite Controllers and Viremic Progressors. PLoS ONE, 2014, 9, e106360.	2.5	52
29	Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation. Journal of the International AIDS Society, 2014, 17, 19246.	3.0	17
30	Immunological Function Restoration with Lopinavir/Ritonavir Versus Efavirenz Containing Regimens in HIV-Infected Patients: A Randomized Clinical Trial. AIDS Research and Human Retroviruses, 2014, 30, 425-433.	1.1	8
31	A Dendritic Cell–Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication. Science Translational Medicine, 2013, 5, 166ra2.	12.4	193
32	Dendritic cell based vaccines for HIV infection. Human Vaccines and Immunotherapeutics, 2013, 9, 2445-2452.	3.3	57
33	Comparison of two <scp>HIV</scp> testing strategies in primary care centres: indicatorâ€conditionâ€guided testing <i>vs</i> . testing of those with nonâ€indicator conditions. HIV Medicine, 2013, 14, 33-37.	2.2	21
34	Rate and Predictors of Non-AIDS Events in a Cohort of HIV-Infected Patients with a CD4 T Cell Count Above 500 Cells/mm ³ . AIDS Research and Human Retroviruses, 2013, 29, 1161-1167.	1.1	39
35	Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV) Tj ETQq1	1 0.784314	4 rgBT /Over 145
36	Post-Exposure Prophylaxis for HIV Infection: A Clinical Trial Comparing Lopinavir/Ritonavir versus	1.0	24

Atazanavir Each with Zidovudine/Lamivudine. Antiviral Therapy, 2012, 17, 337-346.

1.024

#	Article	IF	CITATIONS
37	Reasons for Not Participating in a Phase 1 Preventive HIV Vaccine Study in a Resource-Rich Country. AIDS Patient Care and STDs, 2012, 26, 379-382.	2.5	4
38	Therapeutic vaccines against HIV infection. Human Vaccines and Immunotherapeutics, 2012, 8, 569-581.	3.3	55
39	Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. Vaccine, 2012, 30, 3703-3709.	3.8	22
40	Loading dendritic cells from HIV-1 infected patients with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses. Retrovirology, 2012, 9, .	2.0	0
41	Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines. Vaccine, 2011, 29, 5711-5724.	3.8	9
42	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVACO2). Vaccine, 2011, 29, 8309-8316.	3.8	70
43	Lymphoid Tissue Collagen Deposition in HIV-Infected Patients Correlates With the Imbalance Between Matrix Metalloproteinases and Their Inhibitors. Journal of Infectious Diseases, 2011, 203, 810-813.	4.0	19
44	A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. Journal of Infectious Diseases, 2011, 203, 473-478.	4.0	105
45	A New Multidisciplinary Home Care Telemedicine System to Monitor Stable Chronic Human Immunodeficiency Virus-Infected Patients: A Randomized Study. PLoS ONE, 2011, 6, e14515.	2.5	71
46	Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. Aids, 2010, 24, F1-F9.	2.2	60
47	Effect of TNF-α genetic variants and CCR5Δ32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards. BMC Medical Genetics, 2010, 11, 63.	2.1	24
48	Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients. Aids, 2010, 24, 2029-2039.	2.2	37
49	Increased Î \pm -Defensins 1-3 Production by Dendritic Cells in HIV-Infected Individuals Is Associated with Slower Disease Progression. PLoS ONE, 2010, 5, e9436.	2.5	40
50	Assessment of migration of HIV-1-loaded dendritic cells labeled with ¹¹¹ In-oxine used as a therapeutic vaccine in HIV-1-infected patients. Immunotherapy, 2009, 1, 347-354.	2.0	8
51	P18-07. Ex vivo production of autologous HIV-1 to be used as immunogen in autologous dendritic cell-based therapeutic vaccine (clinical trial DCV02). Retrovirology, 2009, 6, .	2.0	0
52	Temporal Data Mining of HIV Registries: Results from a 25 Years Follow-Up. Lecture Notes in Computer Science, 2009, , 56-60.	1.3	1
53	Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts [*] . HIV Medicine, 2008, 9, 221-226.	2.2	55
54	Short Communication: Natural Killer Cells and Expression of KIR Receptors in Chronic HIV Type 1-Infected Patients after Different Strategies of Structured Therapy Interruption. AIDS Research and Human Retroviruses, 2008, 24, 1485-1495.	1.1	6

#	Article	IF	CITATIONS
55	Zidovudine/Lamivudine/Abacavir Plus Tenofovir in HIV-Infected Naive Patients: A 96-Week Prospective One-Arm Pilot Study. AIDS Research and Human Retroviruses, 2008, 24, 931-934.	1.1	8
56	Prevalence and Clinical Relevance of Occult Hepatitis B in the Fibrosis Progression and Antiviral Response to INF Therapy in HIV–HCV-Coinfected Patients. AIDS Research and Human Retroviruses, 2008, 24, 547-553.	1.1	15
57	Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption. Journal of Antimicrobial Chemotherapy, 2008, 63, 184-188.	3.0	8
58	Predictive Value of Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients Treated With an Interferon-Based Regimen Plus Ribavirin. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 174-178.	2.1	29
59	Noninvasive Diagnosis of Hepatic Fibrosis in HIV/HCV-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 304-311.	2.1	36
60	Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues. Journal of Antimicrobial Chemotherapy, 2007, 60, 824-830.	3.0	13
61	Clinicoimmunological Progression and Response to Treatment of Long-Term Nonprogressor HIV–Hepatitis C Virus-Coinfected Patients. AIDS Research and Human Retroviruses, 2007, 23, 863-867.	1.1	6
62	P1912 Efficacy and safety of tenofovir, abacavir and efavirenz in treatment–naÃ⁻ve patients:48-week results (The ABATE Trial). International Journal of Antimicrobial Agents, 2007, 29, S548-S549.	2.5	0
63	Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count?300 cells/?L who were assigned to 7.5 MIU interleukin-2. HIV Medicine, 2007, 8, 112-123.	2.2	7
64	Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Medicine, 2007, 8, 251-258.	2.2	110
65	The Impact of Reducing Stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antiviral Therapy, 2007, 12, 407-416.	1.0	60
66	Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations. Aids, 2006, 20, 1891-1892.	2.2	5
67	Intrathoracic fat in HIV-infected patients. HIV Medicine, 2006, 7, 213-217.	2.2	4
68	Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. Aids, 2006, 20, 59-66.	2.2	153
69	Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor. Aids, 2005, 19, 829-831.	2.2	3
70	High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir. Aids, 2005, 19, 1695-1697.	2.2	18
71	Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. Aids, 2005, 19, 213-215.	2.2	48
72	Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antiviral Therapy, 2005, 10, 423-9.	1.0	10

#	Article	IF	CITATIONS
73	Incidence and Risk Factors for Mitochondrial Toxicity in Treated HIV/HCV-Coinfected Patients. Antiviral Therapy, 2005, 10, 423-429.	1.0	36
74	Early Virological Failure with a Combination of Tenofovir, Didanosine and Efavirenz. Antiviral Therapy, 2005, 10, 171-177.	1.0	47
75	Risk of Metabolic Abnormalities in Patients Infected with HIV Receiving Antiretroviral Therapy that Contains Lopinavirâ€Ritonavir. Clinical Infectious Diseases, 2004, 38, 1017-1023.	5.8	75
76	Gynecomastia among HIV-Infected Patients Is Associated with Hypogonadism: A Case-Control Study. Clinical Infectious Diseases, 2004, 39, 1514-1519.	5.8	33
77	Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. Aids, 2004, 18, 27-36.	2.2	343
78	Depressive Symptoms after Initiation of Interferon Therapy in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C. Antiviral Therapy, 2004, 9, 905-909.	1.0	32
79	Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection. New England Journal of Medicine, 2003, 349, 1036-1046.	27.0	303